Levothyroxine Sodium Tablets recalled nationwide for potency failures
Viatris Inc. is recalling 19,549 bottles of Levothyroxine Sodium 175 mcg tablets nationwide due to potency failures. Some tablets contain excessive active ingredient while others contain insufficient amounts.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II drug recall for potency failures in a critical thyroid medication. No illnesses or injuries have been reported. Per the severity rubric, this qualifies as a risk-of-harm product where injury has not yet been reported, warranting a High classification.
Plain-English summary
Viatris Inc. is recalling Levothyroxine Sodium Tablets USP, 175 micrograms, distributed nationwide in the United States and Puerto Rico. The recall affects approximately 19,549 bottles in two package sizes: 90-count bottles (NDC 0378-1817-77) and 1000-count bottles (NDC 0378-1817-10).
The recall was initiated due to potency failures identified in certain batches. Some tablets contain higher-than-specified amounts of active ingredient (superpotent), while others contain lower-than-specified amounts (subpotent). Affected lots include 3192915 and 8172108 (with March 2025 expiration dates) for 90-count bottles, and lot 3208680 (with September 2025 expiration date) for 1000-count bottles.
Patients currently taking levothyroxine should check their prescription against the affected lot numbers and expiration dates listed above. Those with recalled medication should contact their pharmacist or healthcare provider for guidance on potential replacement or next steps.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Viatris Inc
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot #: a) 3192915
- 8172108
- Exp. Date Mar 2025
- b) 3208680
- Exp. Date Sep 2025
Distribution
Part of a larger recall action
This product is one of 11 recalled by Viatris Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 11 products in this recall →Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same manufacturer · Viatris Inc
See all →- HighXanax XR 3 mg extended-release tablets fail dissolution specifications
FDA (Drugs) · 2026-04-15
- ModeratePrescription Drug Cardura XL Recalled for Out-of-Specification Impurity
FDA (Drugs) · 2025-01-22
- HighPrescription Drug Cardura Recalled for Specification Failures in Manufacturing
FDA (Drugs) · 2025-01-22
- HighLevothyroxine sodium tablets recalled for potency failures nationwide
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
Same hazard · potency failure
See all →- Moderateglo Skin Beauty Remedy Gel recalled as a subpotent hydrocortisone product
FDA (Drugs) · 2026-04-22
- ModerateRhonda Allison calming skin gel recalled as a subpotent hydrocortisone product
FDA (Drugs) · 2026-04-22
- ModerateAvantor magnesium chloride active pharmaceutical ingredient recalled as subpotent
FDA (Drugs) · 2026-04-22
- ModerateSkin Rehab calming hydrocortisone balm recalled as a subpotent drug
FDA (Drugs) · 2026-04-22
- HighTeva isotretinoin 40 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15